세계 BCMA 표적요법 시장 : 유형별, 암별, 최종사용자별, 국가별, 지역별: 산업 분석 : 시장 규모, 시장 점유율 및 예측(2024년-2032년)

REPORT HIGHLIGHT

Bcma Targeted Therapies Market size was valued at USD 9,010 Million in 2023, expanding at a CAGR of 20.5% from 2024 to 2032.

BCMA, or B cell maturation antigen, has emerged as a promising treatment target for multiple myeloma (MM) due to its highly specific expression in malignant plasma cells (PCs). Various BCMA-targeted therapies, such as antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have shown remarkable clinical responses in patients with relapsed and refractory MM. The introduction of novel therapeutics like proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has further enhanced the treatment outcomes for patients with MM. It is estimated that there will be over 275,000 new cases of multiple myeloma worldwide by 2040. Multiple myeloma is a type of blood cancer characterized by the abnormal proliferation of malignant plasma cells, primarily originating in the bone marrow. BCMA, a cell surface antigen predominantly found in multiple myeloma cases, presents a valuable target for therapeutic interventions in this disease.

Bcma Targeted Therapies Market- Market Dynamics

Increasing number of recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market

BCMA-targeted therapies, such as targeted treatments, provide a more precise method by specifically focusing on cancer cells that express BCMA. This approach has the potential to result in treatments that are more effective and less harmful, thereby addressing the unmet medical requirements. According to the American Society of Clinical Oncology, In 2023, an estimated 35,730 adults (19,860 men and 15,870 women) in the United States will be diagnosed with multiple myeloma. Worldwide, an estimated 176,404 people were diagnosed with multiple myeloma in 2020. Additionally, ongoing advancements in comprehending the molecular and genetic foundations of multiple myeloma may lead to the identification of new therapeutic targets and the development of more potent BCMA-targeted therapies. However, it is important to note that the high cost of these therapies may hinder market growth.

Bcma Targeted Therapies Market- Key Insights

• As per the analysis shared by our research analyst, the global Bcma Targeted Therapies market is estimated to grow annually at a CAGR of around 20.5% over the forecast period (2024-2032)

• Based on Type segmentation, Chimeric Antigen Receptor T-Cells was predicted to show maximum market share in the year 2023

• Based on End-User segmentation, Hospitals was the leading type in 2023

• On the basis of region, North America was the leading revenue generator in 2023

Bcma Targeted Therapies Market- Segmentation Analysis:

The Global Bcma Targeted Therapies Market is segmented on the basis of Type, Cancer, End-User, and Region.

The market is divided into three categories based on Type: Bispecific Antibodies, Antibody Drug Conjugates and Chimeric Antigen Receptor T-Cells.The market is largely dominated by the segment of Chimeric Antigen Receptor T-Cells. Multiple myeloma cells, which are a type of cancer that affects plasma cells, express a protein called BCMA on their surface. CAR-T cell therapy is an immunotherapy approach that involves modifying the patient's own T cells to express a chimeric antigen receptor (CAR) capable of identifying and attacking cancer cells.

The market is segmented into three groups according to the type of cancer: Liver Cancer, Respiratory Cancer, Brain Cancer, and Others. B-Cell Maturation Antigen (BCMA) targeted therapies have mainly been used in the treatment of multiple myeloma, a form of cancer that impacts plasma cells. BCMA is present on the surface of multiple myeloma cells, which makes it a prime target for therapeutic interventions.

The market is divided into two categories based on End-User: Hospitals and Cancer Research Institute. The market is largely controlled by the hospitals sector. In order to improve patient care and support services, hospitals may have to focus on managing the potential side effects of BCMA-targeted therapies and providing comprehensive care for patients receiving treatment. It is crucial for hospitals to comply with regulatory requirements for the administration of cancer treatments, ensuring that protocols are in line with the safety and efficacy standards set by health authorities.

Bcma Targeted Therapies Market- Geographical Insights

Geographically, this market is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increasing investments in research and development of innovative therapies for multiple myeloma. The United States serves as a major center for clinical research, hosting numerous clinical trials for various diseases, including multiple myeloma. The presence of renowned research institutions, academic medical centers, and biotechnology companies contributes to a strong infrastructure for conducting clinical trials, thereby facilitating the development of new therapies. According to the National Health Expenditures, the United States (U.S.) witnessed a significant increase in medical and health research and development (R&D) investment, reaching USD 245.1 billion in 2020, marking an 11.1% rise from 2019. The growth rates in the public-private sector R&D ecosystem underwent changes in 2020, likely influenced by the response to and impact of the COVID-19 pandemic.

Bcma Targeted Therapies Market- Competitive Landscape:

The BCMA-targeted therapies market is characterized by a dynamic competitive landscape, with numerous pharmaceutical and biotechnology companies actively engaged in the development of these treatments. These therapies have demonstrated clinical effectiveness in addressing multiple myeloma, particularly in patients who have relapsed or shown resistance to other treatment options. Many companies are currently involved in both preclinical and clinical stages of developing BCMA-targeted therapies, either as standalone treatments or in combination with other drugs. As an example, on January 31, 2023, Poseida Therapeutics, Inc., a clinical-stage company specializing in cell and gene therapy, announced the resignation of Dr. Eric Ostertag, M.D., Ph.D., as Executive Chairman and his retirement from the Board of Directors, effective February 3, 2023. However, Dr. Ostertag will continue to contribute to the company as a consultant, providing valuable expertise in technical and scientific matters.

Recent Developments:

November 17, 2022, More than 275,000 new cases of multiple myeloma are expected to occur globally by the year 2040. Multiple myeloma is a blood cancer characterized by the proliferation of malignant plasma cells that typically originate in the bone marrow. B-cell maturation antigen (BCMA) is an important cell surface antigen found in nearly all cases of multiple myeloma, but with limited expression on normal tissues other than plasma cells. This makes it a key target for multiple myeloma therapeutics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BCMA TARGETED THERAPIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• Transposagen Biopharmaceuticals
• Sutro Biopharma
• Malin Corporation
• Eureka Therapeutics
• firstVentury Equity
• Five Prime Therapeutics
• Credit Suisse Securities
• Dana-Farber Cancer Institute
• Deerfield Partners
• Onyx Pharmaceuticals
• Juno Therapeutics

GLOBAL BCMA TARGETED THERAPIES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

• Bispecific Antibodies
• Antibody Drug Conjugates
• Chimeric Antigen Receptor T-Cells

GLOBAL BCMA TARGETED THERAPIES MARKET, BY CANCER- MARKET ANALYSIS, 2019 - 2032

• Liver Cancer
• Respiratory Cancer
• Brain Cancer
• Others

GLOBAL BCMA TARGETED THERAPIES MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

• Hospitals
• Cancer Research Institute

GLOBAL BCMA TARGETED THERAPIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Bcma Targeted Therapies Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Bcma Targeted Therapies Market Snippet by Type
  • 2.1.2. Bcma Targeted Therapies Market Snippet by Cancer
  • 2.1.3. Bcma Targeted Therapies Market Snippet by End-User
  • 2.1.4. Bcma Targeted Therapies Market Snippet by Country
  • 2.1.5. Bcma Targeted Therapies Market Snippet by Region
• 2.2. Competitive Insights

3. Bcma Targeted Therapies Key Market Trends

• 3.1. Bcma Targeted Therapies Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Bcma Targeted Therapies Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Bcma Targeted Therapies Market Opportunities
• 3.4. Bcma Targeted Therapies Market Future Trends

4. Bcma Targeted Therapies Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Bcma Targeted Therapies Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Bcma Targeted Therapies Market Landscape

• 6.1. Bcma Targeted Therapies Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Bcma Targeted Therapies Market - By Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
  • 7.1.2. Bispecific Antibodies
  • 7.1.3. Antibody Drug Conjugates
  • 7.1.4. Chimeric Antigen Receptor T-Cells

8. Bcma Targeted Therapies Market - By Cancer

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Cancer, 2023 & 2032 (%)
  • 8.1.2. Liver Cancer
  • 8.1.3. Respiratory Cancer
  • 8.1.4. Brain Cancer
  • 8.1.5. Others

9. Bcma Targeted Therapies Market - By End-User

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
  • 9.1.2. Hospitals
  • 9.1.3. Cancer Research Institute

10. Bcma Targeted Therapies Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Bcma Targeted Therapies Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Bcma Targeted Therapies Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Bcma Targeted Therapies Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Bcma Targeted Therapies Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Bcma Targeted Therapies Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bcma Targeted Therapies Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Transposagen Biopharmaceuticals
  • 11.2.2. Sutro Biopharma
  • 11.2.3. Malin Corporation
  • 11.2.4. Eureka Therapeutics
  • 11.2.5. firstVentury Equity
  • 11.2.6. Five Prime Therapeutics
  • 11.2.7. Credit Suisse Securities
  • 11.2.8. Dana-Farber Cancer Institute
  • 11.2.9. Deerfield Partners
  • 11.2.10. Onyx Pharmaceuticals
  • 11.2.11. Juno Therapeutics

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us